Genetic assessment following increased nuchal translucency and normal karyotype

The objective of this study was to assess the first formal approach for monitoring genetic/developmental syndromes associated with the presence of an increased nuchal translucency (NT) thickness (>3 mm) in the first trimester of pregnancy.

[1]  Suseela Vavilala,et al.  The 11-13+6 Weeks Scan: Where do We Stand? A 5-year Review at Fernandez Hospital , 2011 .

[2]  K. Nicolaides,et al.  First Trimester Ultrasound Screening: An Update , 2010 .

[3]  C. Bilardo,et al.  Increased nuchal translucency in euploid fetuses—what should we be telling the parents? , 2010, Prenatal diagnosis.

[4]  B. Gelb,et al.  Noonan Syndrome: Clinical Aspects and Molecular Pathogenesis , 2010, Molecular Syndromology.

[5]  P. Trompoukis,et al.  An update to 21-hydroxylase deficient congenital adrenal hyperplasia , 2009, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[6]  E. Pajkrt,et al.  Male gender as a favorable prognostic factor in pregnancies with enlarged nuchal translucency , 2009, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[7]  S. Kjaergaard,et al.  Testing for 22q11 microdeletion in 146 fetuses with nuchal translucency above the 99th percentile and a normal karyotype , 2008, Acta obstetricia et gynecologica Scandinavica.

[8]  R. Shprintzen.  Velo-cardio-facial syndrome: 30 Years of study. , 2008, Developmental disabilities research reviews.

[9]  B. Chong,et al.  Population screening and cascade testing for carriers of SMA , 2007, European Journal of Human Genetics.

[10]  I. Schrijver,et al.  Comprehensive arrayed primer extension array for the detection of 59 sequence variants in 15 conditions prevalent among the (Ashkenazi) Jewish population. , 2007, The Journal of molecular diagnostics : JMD.

[11]  R. Kucherlapati,et al.  A novel, single nucleotide polymorphism-based assay to detect 22q11 deletions. , 2007, Genetic testing.

[12]  J. Douketis,et al.  DHCR7 mutation carrier rates and prevalence of the RSH/Smith‐Lemli‐Opitz syndrome: Where are the patients? , 2006, American journal of medical genetics. Part A.

[13]  A. Donnenfeld,et al.  Prospective study of 22q11 deletion analysis in fetuses with excess nuchal translucency. , 2006, American journal of obstetrics and gynecology.

[14]  K. Nicolaides,et al.  Increased nuchal translucency with normal karyotype. , 2005, American journal of obstetrics and gynecology.

[15]  B. Thilaganathan,et al.  Significance of chromosome 22q11 analysis after detection of an increased first‐trimester nuchal translucency , 2001, Ultrasound in Obstetrics and Gynecology.

[16]  A. Metspalu,et al.  Unravelling Genetic Data by Arrayed Primer Extension , 2000, Clinical chemistry and laboratory medicine.

[17]  A. Metspalu,et al.  Arrayed primer extension: solid-phase four-color DNA resequencing and mutation detection technology. , 2000, Genetic testing.

[18]  K. Nicolaides,et al.  Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study , 1999, BMJ.